Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary

Incidence of low grade well-differentiated neuroendocrine tumors (NET) is on the rise. The North American Neuroendocrine Tumor Society estimates that the United States has more than 150,000 gastroenteropancreatic NET patients. About 10% of metastatic NETs can be unknown primary, and due to their rar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Oncol
Main Authors: Chauhan, Aman, Farooqui, Zainab, Murray, Le Aundra, Weiss, Heidi L., War Myint, Zin, Raajasekar, Arun Kumar A., Evers, B. Mark, Arnold, Susanne, Anthony, Lowell
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5964580/
https://ncbi.nlm.nih.gov/pubmed/29853889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/3519247
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados